Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock




Bright Minds Biosciences Announces Pricing of Upsized US$175 Million Public Offering of Common Stock

NEW YORK, Jan. 07, 2026 (GLOBE NEWSWIRE) — Bright Minds Biosciences Inc. (CSE: DRUG) (NASDAQ: DRUG) (“Bright Minds” or the “Company”) announces the pricing of its previously announced public offering of 1,945,000 common shares in the capital of the Company (the “Common Shares”) at a price of $90.00 per Common Share for anticipated gross proceeds of $175,050,000 (the “Offering”). In connection with the Offering, the Company has granted the underwriters a 30-day option to purchase up to an additional 291,750 Common Shares at the public offering price, less underwriting discounts and commissions. All of the securities being sold in this Offering are being offered by Bright Minds.

The closing of the Offering is expected to occur on January 9, 2026 subject to the satisfaction of customary closing conditions.

The Company intends to use the net proceeds from the Offering to fund future clinical trials for the Company’s drug candidates, including for absence seizures, DEE, and Prader-Willi Syndrome, as well as initiation of phase 1 clinical drug trials for BMB-105, and additional research and development work on earlier phase programs, as well as for general corporate and working capital purposes.

Jefferies, TD Cowen, Piper Sandler & Co., and Cantor are acting as joint book-running managers for the Offering.

The Company has filed a shelf registration statement on Form F-3 (the “Registration Statement”) with the U.S. Securities and Exchange Commission (“SEC”) which was declared effective by the SEC on September 2, 2025. The Offering is being made solely by means of a prospectus and a prospectus supplement that form a part of the Registration Statement. A copy of the preliminary prospectus supplement and accompanying prospectus relating to this Offering has been filed with the SEC. Before you invest, you should read the prospectus in that Registration Statement and other documents the Company has filed with the SEC for more information about the Company and the Offering. You may get these documents for free by visiting EDGAR on the SEC website at www.sec.gov. The final terms of the Offering will be disclosed in a final prospectus supplement to be filed with the SEC. Copies of the preliminary prospectus supplement and accompanying prospectus, and the final prospectus supplement, once available, relating to the Offering may be obtained from (i) Jefferies LLC, Attention: Equity Syndicate Prospectus Department, 520 Madison Avenue, New York, New York 10022, by telephone at (877) 821-7388 or by email at Prospectus_Department@Jefferies.com, (ii) TD Securities (USA) LLC, c/o Broadridge Financial Solutions, 1155 Long Island Avenue, Edgewood, NY 11717, or by email at TDManualrequest@broadridge.com, (iii) Piper Sandler & Co., Attention: Prospectus Department, 350 North 5th Street, Suite 1000, Minneapolis, Minnesota 55401, or by telephone at (800) 747-3924, or by e-mail at prospectus@psc.com, or (iv) Cantor Fitzgerald & Co., Attention: Capital Markets, 110 East 59th Street, 6th Floor, New York, New York 10022, or by email at prospectus@cantor.com.

Termination of ATM

The Company also announces that in connection with pricing the Offering, the Company has terminated the equity distribution agreement dated August 25, 2025 (the “EDA”) entered into among the Company, Piper Sandler & Co. and Cantor Fitzgerald & Co. (collectively, the “Agents”), providing for an at-the-market equity offering program (the “ATM”), with such termination effective today. The ATM previously allowed the Company to issue and sell Common Shares from treasury having an aggregate gross sales amount of up to USD$100 million through the Agents.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or jurisdiction in which such offer, solicitation or sale would be unlawful prior to registration or qualification under the securities laws of any such state or jurisdiction. Any offers, solicitations or offers to buy, or any sales of securities will be made in accordance with the registration requirements of the Securities Act of 1933, as amended.

About Bright Minds

Bright Minds is a biotechnology company developing innovative treatments for patients with neurological and psychiatric disorders. Our pipeline includes novel compounds targeting key receptors in the brain to address conditions with high unmet medical need, including epilepsy, depression, and other CNS disorders. Bright Minds is focused on delivering breakthrough therapies that can transform patients’ lives.

Bright Minds has developed a unique platform of highly selective serotonergic agonists exhibiting selectivity at different serotonergic receptors. This has provided a rich portfolio of NCE programs within neurology and psychiatry.

Contact Information

Alex Vasilkevich
Chief Operating Officer
Bright Minds Biosciences Inc.
T: 414-731-6422
E: alex@brightmindsbio.com

Investor Relations

Lisa M. Wilson
T: 212-452-2793
E: lwilson@insitecony.com

The Canadian Securities Exchange has neither approved nor disapproved the contents of this news release.

Forward-Looking Information

This document contains “forward-looking statements” that were based on the Company’s expectations, estimates and projections as of the dates those statements were made. Generally, these forward-looking statements can be identified by the use of forward-looking terminology such as “outlook”, “anticipate”, “project”, “target”, “believe”, “estimate”, “expect”, “intend”, “should” and similar expressions. Forward-looking statements made in this news release include statements regarding the sales of securities pursuant to the Offering and the Company’s use of proceeds from the Offering.

Forward-looking statements are subject to known and unknown risks, uncertainties and other factors that may cause the Company’s actual results, level of activity, performance or achievements to be materially different from those expressed or implied by such forward-looking statements. These included but are not limited to:

• changes in general economic conditions, the financial markets, inflation and interest rates, fluctuations in exchange rates, particularly with respect to the value of the U.S. dollar and Canadian dollar, and the continued availability of capital and financing;
• inherent risks associated with pharmaceutical companies, including with respect to outcomes of testing of potential drug candidates, compliance with regulatory requirements from all jurisdictions in which the Company operates or may operate, and competition;
• the risk of inadequate insurance or inability to obtain insurance to cover operational risks;
• our ability to comply with the extensive governmental regulation to which our business is subject;
• uncertainties related to unexpected judicial or regulatory proceedings;  
• changes in, and the effects of, the laws, regulations and government policies affecting our intellectual property, pre-clinical and clinical drug trials;
• litigation risks and the inherent uncertainty of litigation;
• our reliance upon key management and operating personnel;
• the competitive environment in which we operate;
• the risk of changes in accounting policies and methods we use to report our financial condition, including uncertainties associated with critical accounting assumptions and estimates;
• Management Discussion and Analysis (“MD&A”), quarterly reports and material change reports filed with and furnished to securities regulators, and those risks which are discussed under the heading “Risk Factors”; and
• whether or not the proposed Offering will be completed, and the risks and uncertainties related to the expected use of proceeds.

For further information on Bright Minds, investors should review the Company’s annual Form 40-F filing with the United States Securities and Exchange Commission available at www.sec.gov and home jurisdiction filings that are available at www.sedarplus.ca, including the “Risk Factors” included in our Annual Information Form.

Best Oral Peptides for Weight Loss: Injectable vs Sublingual vs Daily Pill – Direct Meds Consumer Analysis




Best Oral Peptides for Weight Loss: Injectable vs Sublingual vs Daily Pill – Direct Meds Consumer Analysis

January 2026 Wellness Season: Format Comparison for Needle-Free GLP-1 Options, Administration Preferences, and Telehealth Access Pathways

HOUSTON, TX, Jan. 07, 2026 (GLOBE NEWSWIRE) — Disclaimer: This article is for informational purposes only. It is not medical advice. Medical decisions about prescription weight-management treatments are appropriately made with a qualified clinician who can evaluate individual risks and eligibility. If you purchase through links in this article, a commission may be earned at no additional cost to you.

Compounded Medication Notice: Compounded medications are not FDA-approved. They are prepared by licensed compounding pharmacies under the supervision of healthcare providers. These formulations may differ in safety, effectiveness, and quality from FDA-approved products. Only a licensed provider can determine whether a compounded medication is appropriate for an individual patient.

January 2026 is aligning with commonly observed early-year interest in oral GLP-1 peptide options, as consumers compare different administration formats during seasonal “new year, new you” wellness behavior.

This Direct Meds Consumer Analysis examines oral peptide weight loss formats within the broader context of how shoppers evaluate injectable versus oral GLP-1 administration methods, including the newly available FDA-approved oral semaglutide option, compounded sublingual semaglutide, and compounded sublingual tirzepatide options.

Note on wording: This report uses “best oral peptides” to reflect common search language. It does not claim any product is best for all people and does not evaluate medical outcomes.

Why “Best Oral Peptides” Searches Increase Every January

Seasonal patterns are commonly observed in wellness search behavior, particularly during the first quarter as consumers compare injectable formats, sublingual drops, and the newly available FDA-approved oral pill during annual wellness reset season.

Common related queries include “best oral peptides for weight loss,” “oral semaglutide,” “sublingual GLP-1,” and “needle-free weight loss medication,” reflecting how the term can point to multiple formats rather than a single product type. The search term captures a wide range of delivery methods—from compounded sublingual drops to the new FDA-approved Wegovy tablet—all designed to offer needle-free alternatives for GLP-1 medication access.

The “best [medication type]” search pattern appears consistently across wellness categories during January. Whether consumers search for GLP-1 peptide options, needle-free alternatives, or telehealth-accessible weight management programs, the underlying question remains the same: which delivery method fits my comfort level and existing routine? In consumer decision-making, format preference is often a practical tie-breaker—especially for people who prioritize routine fit and comfort with administration.

Coverage discussing how different peptide formats compare for weight management has increased across financial and consumer media outlets, highlighting the importance of understanding the distinction between FDA-approved and compounded options for informed evaluation.

What “Best” Means for Different Oral Peptide Formats

When consumers search for “best oral peptides for weight loss,” they’re evaluating products across multiple dimensions. This Direct Meds Consumer Analysis examines criteria that influence consumer decision-making:

Format Preference: Different people prefer different administration methods. Some prefer the convenience of a once-daily pill like the new FDA-approved Wegovy tablet. Others prefer compounded sublingual drops that absorb under the tongue. Some remain comfortable with weekly injections despite needle requirements.

Regulatory Framework Understanding: Consumers increasingly recognize the distinction between FDA-approved finished products and compounded medications prepared by licensed pharmacies under federal and state compounding regulations.

Cost Accessibility: If price determines whether ongoing treatment is financially sustainable, understanding the difference between branded medication pricing and compounded alternatives becomes central to the decision-making process.

Lifestyle Fit: Whether an oral peptide option fits someone’s lifestyle depends on factors including administration timing requirements, travel frequency, work schedule, and personal comfort with different delivery formats.

Oral Peptide Delivery Formats Consumers Compare Most

When researching oral peptide options for weight loss, consumers encounter three primary format categories:

Category 1: FDA-Approved Oral Wegovy (Semaglutide Tablets)

According to Novo Nordisk communications and FDA-approved prescribing information, oral Wegovy is FDA-approved as an oral GLP-1 option for chronic weight management. The daily tablet requires specific administration timing according to prescribing information. Publicly available manufacturer and pharmacy disclosures have referenced cash-pay pricing for oral Wegovy that may fall within a mid-hundreds monthly range, depending on dose, pharmacy, and availability. Actual pricing, insurance coverage, and patient costs vary significantly and can be confirmed directly through prescribing providers and pharmacies.

According to Novo Nordisk’s published phase III clinical trial data submitted to the FDA, participants assigned to oral Wegovy experienced average weight reduction outcomes in the low-to-mid-teens percentage range over the study period, while placebo groups demonstrated substantially lower changes. Individual results varied, and these findings reflect controlled clinical trial conditions rather than real-world outcomes.

Category 2: Compounded Sublingual GLP-1 Drops

Compounded sublingual formulations—including semaglutide and tirzepatide drops—are prepared by licensed 503A compounding pharmacies under federal and state compounding regulations. These formulations are placed under the tongue for absorption through the mucous membranes.

Direct Meds offers compounded sublingual options in this category. According to the company’s website, sublingual semaglutide is available at $299 per month and sublingual tirzepatide at $349 per month based on platform-displayed pricing at the time of review. These compounded versions are not FDA-approved finished products.

Category 3: Weekly Injectable GLP-1 Medications

Some consumers continue to prefer weekly injectable formats despite oral alternatives. Injectable options include FDA-approved branded medications (Wegovy, Zepbound) and compounded injectable versions available through telehealth platforms. Media coverage examining injectable versus oral GLP-1 access pathways reflects growing consumer interest in how format differences influence treatment preferences.

The term “best oral peptides” in consumer searches encompasses the first two categories. Understanding which format aligns with individual preferences determines which option represents “best” for that person.

Regulatory Context: FDA-Approved vs Compounded Oral Peptides

For consumers researching oral peptide options, understanding the regulatory distinction is essential for informed decision-making.

FDA-Approved Oral Wegovy: Oral Wegovy is an FDA-approved finished product that has undergone full regulatory review with extensive clinical trial data demonstrating safety and effectiveness for chronic weight management. The FDA requires that medications demonstrate safety and effectiveness through rigorous clinical trial protocols before approval.

Compounded Sublingual Formulations: Compounded medications are prepared by licensed pharmacies based on individual prescriptions using FDA-approved active ingredients, but the finished compounded products themselves are not FDA-approved. According to FDA guidance, the agency does not review compounded versions for safety, effectiveness, or quality before they are marketed or dispensed.

The evidence base differs between these categories. FDA-approved medications have extensive clinical trial data from thousands of participants studied over extended periods. Compounded formulations use the same active ingredients sourced from FDA-registered facilities, but finished formulations and delivery mechanisms have not undergone the same research and approval process.

Brand Research: Direct Meds Oral Peptide Options

According to publicly available information from the Direct Meds website, the platform offers both injectable and oral compounded GLP-1 formulations for patients who qualify through medical evaluation.

Platform Classification and Structure

According to Direct Meds’ terms of use, the platform functions as a telehealth technology company facilitating connections between patients and healthcare providers. Direct Meds itself is not a healthcare provider.

Three-Entity Structure:

Direct Meds (Platform) functions as the telehealth platform facilitating connections between patients and healthcare providers. According to the platform’s terms, Direct Meds itself is not a healthcare provider. The platform provides the technology infrastructure, customer service, and coordination that enables the telehealth experience.

Licensed Medical Providers are independent healthcare professionals who review patient information and determine whether prescriptions are appropriate. These providers make clinical decisions based on the health information patients provide. The platform cannot guarantee that any individual will receive a prescription, as that determination rests entirely with the evaluating clinician.

Partner Pharmacies fulfill prescriptions written by the medical providers. These are licensed U.S. 503A compounding pharmacies that dispense medications according to prescriptions received.

Oral Peptide Options Available

According to the Direct Meds website, the platform offers:

• Sublingual Semaglutide: $299 per month according to current platform pricing
• Sublingual Tirzepatide: $349 per month according to current platform pricing

These sublingual formulations are designed for absorption under the tongue, providing a needle-free administration method for patients who prefer not to self-inject.

What Direct Meds Oral Peptides Are NOT

Based on the company’s own positioning:

• NOT FDA-approved finished products
• NOT positioned as guaranteed weight loss solutions
• NOT appropriate for all patients regardless of medical history
• NOT a replacement for comprehensive medical evaluation

Availability and Policy Information

According to the Direct Meds website, the platform currently does not serve residents of Mississippi or Louisiana where telehealth prescribing of weight-management medications is restricted at the state level. The company states it is working on options for California. Availability of compounded GLP-1 medications may also change based on evolving federal and state enforcement priorities and FDA safety communications, so current service status and pharmacy details can be confirmed directly through the platform.

Readers can view the current Direct Meds oral peptide offerings for the latest pricing, eligibility requirements, and service policies.

Who Different Oral Peptide Formats May Appeal To

Oral peptide options—whether FDA-approved or compounded—may align well with certain consumer profiles:

People Who Prefer Needle-Free Administration: If you experience needle aversion or simply prefer not to self-inject, oral formats including sublingual drops and daily tablets offer practical alternatives to injectable options.

Consumers Who Value Daily Routine Integration: If you prefer incorporating medication into a daily routine rather than tracking weekly injection schedules, oral formats may fit your lifestyle better than once-weekly injectables.

People Seeking Cost-Accessible Alternatives: Publicly available manufacturer and pharmacy disclosures have referenced oral Wegovy self-pay pricing that may vary by dose and pharmacy, while compounded sublingual options through platforms like Direct Meds are displayed at set monthly rates at the time of review. Actual pricing, availability, and patient cost responsibility vary significantly and can be confirmed directly through the relevant prescribing and dispensing channels. For patients without insurance coverage for weight loss medications, understanding these pricing structures helps inform financial planning for ongoing treatment.

Consumers Who Understand the Regulatory Distinction: If you’ve researched the difference between FDA-approved finished products and compounded medications, and you’re comfortable with the appropriate regulatory framework for your preferences, you’re better positioned to make an informed choice.

Situations That Commonly Require Professional Medical Evaluation

People with medical conditions, pregnancy/nursing considerations, or medication use are appropriately evaluated by qualified healthcare professionals before using any GLP-1 medication, whether FDA-approved or compounded.

Specific contraindications according to FDA prescribing information include personal or family history of medullary thyroid carcinoma (MTC) or Multiple Endocrine Neoplasia syndrome type 2 (MEN 2). GLP-1 medications are also not recommended for patients with history of pancreatitis, severe gastrointestinal disease, or certain other conditions.

How to Match Oral Peptide Format to Your Preferences

Consumers comparing oral peptide products commonly review information directly on manufacturer or platform pages: (1) Format (FDA-approved tablet, compounded sublingual drops), (2) regulatory framework and clinical evidence base, (3) pricing structure and included services, and (4) provider evaluation process and platform policies.

This multi-criteria evaluation approach extends across prescription weight management options. The consistent pattern: matching product format to actual administration preferences and financial circumstances determines long-term adherence more than active ingredient selection alone.

Misunderstanding regulatory frameworks leads to mismatched expectations. Someone expecting extensive FDA clinical trial data who receives a compounded formulation may have different expectations than the evidence base supports. Someone prioritizing cost accessibility who focuses only on FDA-approved options may find ongoing treatment financially unsustainable.

If you searched “best oral peptides for weight loss” expecting FDA-approved clinical trial data and found compounded telehealth options, understanding this distinction can help align expectations with the regulatory framework regardless of which path is ultimately chosen with a clinician.

Oral Peptide Administration: What Consumers Commonly Evaluate

When evaluating any oral peptide option, consumers commonly review:

• Administration requirements and timing
• Regulatory framework (FDA-approved vs compounded)
• Clinical evidence supporting the specific formulation
• Pricing structure and included services
• Provider evaluation process and medical oversight

What consumers often miss: confirming that the regulatory framework and evidence base match their expectations. A high-quality compounded option may not satisfy someone expecting FDA clinical trial data. An FDA-approved option may not be financially sustainable without insurance coverage.

Contact Information

For questions before or during the evaluation process, according to the Direct Meds website, the company offers customer support:

Phone: 888-696-7176 Hours: 9am to 9pm ET daily (hours may change) Email: help@directmeds.com

FAQ: Search-Driven Questions About Best Oral Peptide Options

What counts as an oral peptide for weight loss?

The term “oral peptide” in consumer usage encompasses any GLP-1 medication designed for non-injectable administration. This includes FDA-approved daily tablets (oral Wegovy), compounded sublingual drops (placed under the tongue for absorption), and compounded oral solutions.

Are sublingual drops considered oral peptides?

Yes. Sublingual formulations are placed under the tongue rather than swallowed, but they’re commonly categorized as “oral” alternatives to injectable medications in consumer search behavior. The absorption mechanism differs from swallowed tablets, but both avoid the need for injection.

Why do some people prefer sublingual drops over tablets?

Format preferences vary based on individual factors. Some people find sublingual administration more familiar or comfortable. Some prefer the flexibility of compounded formulations. Others prefer the FDA clinical trial data supporting approved tablets despite potentially higher pricing.

Is oral semaglutide used for weight loss?

Yes. FDA-approved oral Wegovy (semaglutide tablets) is specifically approved for chronic weight management in adults with obesity or overweight with weight-related conditions. Compounded sublingual semaglutide is also prescribed for weight management, though compounded formulations have not undergone FDA approval as finished products.

Who is appropriately evaluated by a professional before using oral peptides?

Anyone taking medications, managing diagnosed health conditions, pregnant or nursing, or with health concerns is appropriately evaluated by healthcare providers when considering GLP-1 medication use. Specific contraindications exist for patients with certain thyroid conditions or family history of specific cancers.

How do compounded sublingual drops differ from FDA-approved oral Wegovy?

The primary differences include regulatory framework (FDA-approved vs compounded under pharmacy regulations), clinical evidence (extensive clinical trials vs same active ingredients without finished-product approval), administration method (swallowed tablet vs sublingual absorption), and pricing structure (branded pharmaceutical pricing vs compounded pharmacy pricing).

What does “best oral peptides” actually mean in search terms?

When consumers search “best oral peptides for weight loss,” they’re typically looking for format comparisons, regulatory framework understanding, and help matching products to their specific preferences and financial circumstances. The term reflects a shopping question, not a request for a single universally superior product.

Final Context: Evaluating Oral Peptide Categories

This Direct Meds Consumer Analysis examined oral peptide options within the context of how consumers search for and evaluate needle-free GLP-1 alternatives.

Format Match Determines Individual “Best”

A high-quality FDA-approved tablet remains “wrong” for someone who cannot afford ongoing treatment without insurance coverage. Similarly, an accessible compounded sublingual option doesn’t serve someone who requires FDA clinical trial data for their comfort level. “Best” becomes meaningful only when qualified by regulatory preferences, financial circumstances, and individual priorities.

Direct Meds Occupies the Compounded Telehealth Category

According to Direct Meds’ positioning, the platform offers compounded sublingual GLP-1 formulations including semaglutide and tirzepatide drops prepared by licensed compounding pharmacies under medical supervision. These compounded versions are not FDA-approved finished products. Consumers seeking this specific format and access pathway may find Direct Meds relevant to evaluate. Those seeking FDA-approved options can explore branded medications through traditional healthcare channels.

Individual Evaluation Remains Essential

Individual consumers can review current product specifications on official websites, assess whether the regulatory framework aligns with personal preferences, and consider whether pricing appears financially sustainable for ongoing treatment.

Readers can view the current Direct Meds oral peptide offerings for current pricing and published details.

Conclusion

Searches for “best oral peptides for weight loss” in January 2026 reflect consumers evaluating various needle-free GLP-1 formats as part of wellness planning. Understanding that this term encompasses multiple distinct product categories—from FDA-approved daily tablets to compounded sublingual drops—provides essential context for informed evaluation.

The January 2026 availability of oral Wegovy adds another dimension to a market that now includes multiple administration formats across both FDA-approved and compounded categories. Whether compounded sublingual formulations through telehealth platforms like Direct Meds represent “best” for any individual depends entirely on that person’s preferences, financial circumstances, and priorities regarding regulatory frameworks.

A practical consumer takeaway is that product details, regulatory framework, and total costs are best aligned with individual needs before a purchase decision is made.

Readers can view the current Direct Meds oral peptide offerings for current product specifications.

Product Support: help@directmeds.com Order Support: 888-696-7176 Hours: 9am to 9pm ET daily (hours may change)

Disclaimers

Content and Medical Disclaimer: This article is for informational purposes only and is not a substitute for professional medical advice, diagnosis, or treatment. The descriptions of potential benefits are not guarantees and are not a substitute for an individualized medical evaluation. GLP-1 medications require evaluation by a licensed clinician. The information provided here does not replace the professional judgment of your healthcare provider.

Professional Medical Disclaimer: This article is educational and does not constitute medical advice. Prescription weight loss medications are not substitutes for prescribed medical treatment for any health condition. Individuals taking medications, managing health conditions, or who are pregnant or nursing are appropriately evaluated by qualified healthcare professionals when considering GLP-1 medications. Medication changes are appropriately handled through a prescribing clinician.

Compounded Medication Notice: Direct Meds offers compounded prescription medications prepared by licensed pharmacies based on individual prescriptions. Compounded medications are not reviewed or approved by the FDA as finished products. They are prepared using active ingredients sourced from FDA-registered facilities under the direction of a prescribing clinician.

FDA-Approved vs Compounded Distinction: FDA-approved semaglutide (Wegovy) is a finished product that has undergone full FDA review for safety, effectiveness, and quality for weight management indications. Compounded formulations of semaglutide and tirzepatide available through telehealth platforms have not undergone this same FDA approval process. The evaluating clinician determines whether compounded options are appropriate based on individual health factors.

Results May Vary: Individual results will vary based on factors including age, baseline weight, metabolic health, genetic factors, consistency of medication use, dietary choices, physical activity levels, and other individual variables. While clinical trials show significant average weight loss with FDA-approved GLP-1 medications, results are not guaranteed and compounded formulations have not been evaluated in the same clinical trial framework.

FTC Affiliate Disclosure: This article contains affiliate links. If you purchase through these links, a commission may be earned at no additional cost to you. This compensation does not influence the accuracy, neutrality, or integrity of the information presented. All opinions and descriptions are based on published research and publicly available information.

Pricing Disclaimer: All prices, promotional offers, and company policies mentioned were accurate at the time of publication (January 2026) but are subject to change without notice. Current pricing and terms are best confirmed on the official Direct Meds website before a purchase decision is made.

Publisher Responsibility Disclaimer: The publisher of this article has made every effort to ensure accuracy at the time of publication. We do not accept responsibility for errors, omissions, or outcomes resulting from the use of the information provided. Details can be verified directly with Direct Meds and an appropriate healthcare professional as part of individual decision-making.

Insurance Coverage Note: Many direct-to-consumer prescription weight loss medications are not covered by traditional insurance plans, but coverage policies vary. Benefits can be confirmed directly with an insurer. Some HSA/FSA plans may reimburse qualifying expenses; eligibility depends on the specific plan’s rules.

Regulatory Scrutiny Acknowledgment: Prescription telehealth weight loss services have been under increased regulatory scrutiny in recent years. Consumers evaluating telehealth platforms commonly review current compliance disclosures, pharmacy licensure information, and provider credentialing details as part of due diligence.

This Direct Meds Consumer Analysis is based on publicly available information from Direct Meds, Novo Nordisk manufacturer announcements, and published research on GLP-1 medications. For current product specifications, complete service details, and eligibility requirements, visit the official Direct Meds website.

Related Links:

• Best Peptides for Weight Loss

CONTACT: Phone: US Toll Free (888) 696-7176
Email: help@direct-meds.com
9am to 9pm EST daily

Range Impact Announces Two Major Land Acquisitions in Kentucky and Sale of Abandoned Mine Land Services Business




Range Impact Announces Two Major Land Acquisitions in Kentucky and Sale of Abandoned Mine Land Services Business

CLEVELAND, OHIO, Jan. 07, 2026 (GLOBE NEWSWIRE) — Range Impact, Inc. (OTCQB: RNGE) (“Range Impact” or the “Company”), a public company dedicated to acquiring, reclaiming and repurposing distressed coal mine properties throughout Appalachia, announced the acquisition of the Premier Elkhorn mine complex (“Premier Elkhorn Mine Complex”) and Cambrian Coal mine complex (“Cambrian Coal Mine Complex”), both located in eastern Kentucky, from Continental Land Co., LLC on December 31, 2025. On the same day, the Company sold all the common stock of Collins Building & Contracting, Inc., a wholly owned subsidiary (“Collins Building”), completing the Company’s exit from its abandoned mine land reclamation services business.

Premier Elkhorn and Cambrian Coal Acquisitions

The Company, through a newly created subsidiary, Range Bluegrass Land LLC (“Range Bluegrass”), acquired all of the real and personal property of the Premier Elkhorn Mine Complex and the Cambrian Coal Mine Complex in exchange for assuming the reclamation obligations of the mine permit holder, Reckoning Reclamation LLC.

The Premier Elkhorn Mine Complex is a former coal mine site comprised of approximately 13,000 surface acres and 42,500 mineral interest acres. The Premier Elkhorn Mine Complex contains metallurgical and thermal coal reserves with 34 mining permits and $44 million of reclamation bonds. The Premier Elkhorn Mine Complex also includes significant legacy investments in coal processing infrastructure, rail, roads, and utilities.

The Cambrian Coal Mine Complex is a former coal mine site comprised of approximately 2,600 surface acres and additional leasable acres of mineral interests. The Cambrian Coal Mine Complex contains metallurgical and thermal coal reserves with 9 mining permits and $10 million of reclamation bonds. The Cambrian Coal Mine Complex is located near the Premier Elkhorn Mine Complex and had previously used the Premier Elkhorn Mine Complex’s coal infrastructure, rail, roads, and utilities when it was operating.

In connection with these land acquisitions, Range Bluegrass entered into an Option Agreement with MRR CNG, LLC (“MRR”), a landfill developer and operator, granting MRR the option to acquire approximately 1,500 acres of surface land at the Premier Elkhorn Mine Complex for the future development and operation of a new waste disposal facility. The option grant was effective as of December 31, 2025. MRR paid Range Bluegrass $500,000 at the time of the grant and would be required to pay the fair market value of the land upon exercise.

Range Bluegrass also entered into a Membership Interest Option and Cash Distribution Right Agreement with Wicks Building LLC (“Wicks Building”), an affiliate of MRR, pursuant to which Wicks Building is entitled to receive 50% of any cash distributions made by Range Bluegrass and is permitted to convert such right into the ownership of 50% of the membership interests of Range Bluegrass. This transaction closed on December 31, 2025 and Wicks Building paid Range Bluegrass $500,000 at closing.

The Company also entered into Consulting Agreements with MRR and F & G LLC (“F & G”), an affiliate of MRR, pursuant to which the Company has agreed to provide certain reclamation and bond release services to MRR and F & G in connection with the potential development of MRR’s waste disposal facility at the Premier Elkhorn Mine Complex. The Company received an initial fee of $1.0 million upon execution of the agreements on December 31, 2025, and, unless the agreements are earlier terminated, is scheduled to receive additional fees of $2.0 million in each of 2026 and 2027.

“With the two large acquisitions announced today, the Company now owns four significant land investments – the Fola and Hobet Mine Complexes in West Virginia, and the Premier Elkhorn and Cambrian Coal Mine Complexes in Kentucky – representing ownership of approximately 30,000 acres of surface land and 150,000 acres of mineral interests,” stated Michael Cavanaugh, the Company’s Chief Executive Officer. Cavanaugh continued, “Range is clearly differentiating itself as a creative problem solver for the region’s most difficult social, economic and environmental challenges caused by legacy coal mine sites and is in the process of assembling one of the largest and most unique portfolios of strategic land assets in Appalachia.”

Collins Building Sale

On December 31, 2025, the Company sold all its common stock of Collins Building to Collins Reclamation LLC, an unaffiliated entity, in exchange for Collins Reclamation’s assumption of two remaining abandoned mine land reclamation contracts in West Virginia.

Mr. Cavanaugh noted, “In its early days, Range Impact had focused primarily on generating revenue by providing reclamation and incidental mining and security services to third party mining companies, permit holders and private owners with abandoned mine land property. However, beginning in early 2025, our strategy evolved from a service-based business model to a land ownership business model designed to create shareholder value by unlocking the underlying value of land we own through our reclamation activities, and then creating multiple streams of long-term recurring revenue with a diverse group of third-party lessees focused on next-generation uses.” Mr. Cavanaugh continued, “The Collins Building sale completes our exit from service-based reclamation work for third-party customers and allows our team to focus all of our attention, energy and capital on the reinvigoration and reimagination of former coal mine sites that we own in Appalachia.”

About Range Impact, Inc.

Headquartered in Cleveland, Ohio, Range Impact is a public company (OTC: RNGE) dedicated to improving the health and wellness of people and the planet through a novel and innovative approach to impact investing. Range Impact owns and operates several complementary operating businesses focused on developing long-term solutions to environmental, social, and health challenges, with a particular focus on acquiring, reclaiming and repurposing mine sites and other undervalued land in economically disadvantaged communities throughout Appalachia. Range Impact takes an opportunistic approach to impact investing by leveraging its competitive advantages and looking at solving old problems in new ways. Range Impact seeks to thoughtfully allocate its capital into strategic opportunities that are expected to make a positive impact on the people-planet ecosystem and generate strong investment returns for its shareholders.

Notice Regarding Forward-Looking Statements

This press release contains “forward-looking statements” as that term is defined in Section 27(a) of the Securities Act of 1933, as amended and Section 21(e) of the Securities Exchange Act of 1934, as amended. Statements in this press release which are not purely historical are forward-looking statements and include any statements regarding beliefs, plans, expectations or intentions regarding the future. Although we believe that these statements are based on reasonable assumptions, they are subject to numerous factors that could cause actual outcomes and results to be materially different from those indicated in such statements. Such factors include, among others, the inherent uncertainties associated with new projects, changes in business strategy and new lines of business. These forward-looking statements are made as of the date of this press release, and we assume no obligation to update the forward-looking statements, or to update the reasons why actual results could differ from those projected in the forward-looking statements. Although we believe that any beliefs, plans, expectations and intentions contained in this press release are reasonable, there can be no assurance that any such beliefs, plans, expectations or intentions will prove to be accurate. Investors should consult all of the information set forth herein and should also refer to the risk factors disclosure outlined in our annual report on Form 10-K for the most recent fiscal year, our quarterly reports on Form 10-Q and other periodic reports filed from time-to-time with the Securities and Exchange Commission.

Range Impact, Inc.
Investor Relations
P: +1 (216) 304-6556
E: ir@rangeimpact.com
W: www.rangeimpact.com

LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates




LENZ Therapeutics Reports Fourth Quarter 2025 Preliminary Unaudited Financial Results and Recent Corporate Updates

Launched VIZZ™ (aceclidine ophthalmic solution) 1.44% in October 2025 for the treatment of presbyopia, with broad product availability in mid-November 2025

Achieved approximately $1.6 million in net product revenue with over 20,000 prescriptions filled in Q4 2025

Over 6,500 unique ECPs prescribed VIZZ; more than 55% have prescribed multiple times in Q4 2025

SAN DIEGO, Jan. 07, 2026 (GLOBE NEWSWIRE) — LENZ Therapeutics, Inc. (Nasdaq: LENZ or “LENZ” or the “Company”), a pharmaceutical company focused on the commercialization of VIZZ™ (aceclidine ophthalmic solution) 1.44%, the first and only aceclidine-based eye drop for the treatment of presbyopia, today reported certain preliminary unaudited financial results for the fourth quarter ended December 31, 2025 and recent corporate updates.

“We are proud of the strong execution delivered in our first quarter of launch, as the team established a solid foundation of awareness, confidence, and willingness to prescribe VIZZ across the eye care professional community,” said Eef Schimmelpennink, President and Chief Executive Officer of LENZ Therapeutics. “More than 6,500 eye care professionals have already written a prescription for VIZZ, the majority of whom prescribed multiple times, signaling early confidence in VIZZ as a convenient and effective alternative to reading glasses. At the same time, over 20,000 prescriptions were filled during our first quarter of launch, exceeding our expectations and reinforcing the early momentum behind VIZZ. Building on this progress, and together with our campaign spokesperson Sarah Jessica Parker, we look forward to launching the VIZZ DTC campaign this quarter.”

Fourth Quarter 2025 Commercial Highlights

• First commercial product sale of VIZZ in October 2025, the first and only aceclidine-based eye drop for the treatment of presbyopia
• Full multi-channel access established through epharmacy and substantially all retail pharmacies by mid-November 2025
• VIZZ net product revenue of approximately $1.6 million in Q4 2025
• Over 20,000 prescriptions filled through Q4 2025
• Rapid uptake by prescribing ECPs with over 6,500 unique prescribing ECPs; more than 55% prescribed multiple times in Q4 2025

Additional Recent Corporate Updates

• In January 2026, the Company announced an exclusive commercialization partnership for VIZZ with Lunatus in the Middle East. Under the terms of the agreement, LENZ will receive upfront, regulatory and commercial milestone payments, in addition to a significant share of revenue generated in the region through a pre-determined minimum product supply price. This agreement represents the fourth commercialization partnership for VIZZ outside the United States.

About LENZ Therapeutics

LENZ Therapeutics is a pharmaceutical company focused on the commercialization of VIZZ^TM (aceclidine ophthalmic solution) 1.44%, the first and only FDA-approved aceclidine-based eye drop for the treatment of presbyopia, a condition impacting an estimated 1.8 billion people globally and 128 million people in the United States. LENZ is commercializing VIZZ in the United States and continues to establish licensing partnerships internationally to provide access to VIZZ globally. LENZ is headquartered in San Diego, California. For more information, visit www.VIZZ.com and www.LENZ-tx.com.

About Presbyopia

Presbyopia is the inevitable loss of near vision associated with aging, impacting the daily lives of nearly all people over the age of 45. As people age, the crystalline lens in their eyes gradually hardens and becomes less able to change shape. This loss of elasticity of the lens reduces the ability of the lens to focus incoming light from near objects onto the retina. Adults over 50 years of age lose, on average, 1.5 lines of near vision every six years. Although the progression of presbyopia is gradual, presbyopes often experience an abrupt change in their daily life as the symptoms become more pronounced starting in their mid-40s, when reading glasses or other corrective aids are suddenly necessary to read text or conduct close-up work. Presbyopia is typically self-diagnosed and self-managed with over-the-counter reading glasses, or managed, after evaluation by an ECP, with prescription reading or bifocal glasses or multifocal contact lenses.

About VIZZ (aceclidine ophthalmic solution) 1.44%

VIZZ (aceclidine ophthalmic solution) 1.44% is a once-daily eye drop developed to restore clear near vision for up to 10 hours. Aceclidine is the sole active ingredient in VIZZ and provides rapid and durable near vision improvement. VIZZ is preservative-free and provided in single-dose vials. VIZZ is a predominantly pupil selective miotic that interacts with the iris with minimal ciliary muscle stimulation. VIZZ causes contraction of the iris sphincter muscle, resulting in a pinhole effect that extends depth of focus to improve vision. For more information, please visit www.VIZZ.com.

VIZZ Indication and Important Safety Information

INDICATION

VIZZ (aceclidine ophthalmic solution) 1.44% is a prescription eye drop used to treat age-related blurry near vision (presbyopia) in adults.

IMPORTANT SAFETY INFORMATION

• Do not use VIZZ if allergic to any of the ingredients.
• To help avoid potential eye injury or contamination of the product, do not allow the vial tip to touch the eye or any surfaces. Discard the opened vial immediately after use.
• Contact lenses should be removed before using VIZZ. After dosing, contact lenses can be reinserted after 10 minutes.
• If using more than one topical eye medication, the medicines should be administered at least 5 minutes apart.
• Temporary dim or dark vision may be experienced after using VIZZ. Do not drive or operate machinery if vision is not clear.
• Seek immediate medical care if sudden onset of flashing lights, floaters, or vision loss is experienced.

ADVERSE REACTIONS

The most common reported adverse reactions of participants were instillation site irritation (20%), dim vision (16%), and headache (13%). Adverse reactions reported in >5% of participants were conjunctival hyperemia (8%) and ocular hyperemia (7%). The majority of adverse reactions were mild, transient, and self-resolving.

For additional information, please see the full Prescribing Information available at www.VIZZ.com/full-prescribing-information.pdf.

Forward-Looking Statements

This press release contains forward-looking statements within the meaning of federal securities laws. You can identify forward-looking statements by words such as “may,” “will,” “could,” “can,” “would,” “should,” “expect,” “intend,” “plan,” “anticipate,” “believe,” “estimate,” “predict,” “project,” “potential,” “poised,” “continue,” “ongoing” or the negative of these terms or other comparable terminology, but not all forward-looking statements will contain these words. ” Forward-looking statements in this press release include statements regarding the timing and availability of VIZZ, including the VIZZ DTC campaign; potential market size for VIZZ; its ability to meet patient needs and become standard of care; LENZ commercialization plans, including international partnering plans, and the quotations of LENZ management. These statements are based on numerous assumptions concerning VIZZ, target markets and involve substantial risks, uncertainties and other factors that may cause actual results, levels of activity, performance or achievement to be materially different from the information expressed or implied by these forward-looking statements, including those risk factors described in the section titled “Risk Factors” in our Quarterly Report on Form 10-Q filed for the quarter ended September 30, 2025 and our subsequent filings with the SEC. The unaudited results in this press release, including Q4 2025 net product revenue, are preliminary and subject to the completion of accounting and annual audit procedures and are therefore subject to adjustment. We cannot assure you that the forward-looking statements in this press release or the assumptions upon which they are based will prove to be accurate. The forward-looking statements in this press release are as of the date of this press release. Except as otherwise required by applicable law, LENZ disclaims any duty to update any forward-looking statements. You should, therefore, not rely on these forward-looking statements as representing our views as of any date subsequent to the date of this press release. 

Contact:
Dan Chevallard
LENZ Therapeutics
IR@LENZ-Tx.com 

Correction: Transactions of Managers and Closely Associated Persons




Correction: Transactions of Managers and Closely Associated Persons

Attached are copies of two filings with the Luxembourg Commission de Surveillance du Secteur Financier (CSSF) regarding transactions of managers and closely associated persons. ATP Holdings ehf. announced two transactions, an acquisition of 4,812,257 shares in Alvotech on December 17, 2025, and a sale of 2,110,640 shares in Alvotech on December 19, 2025. The transaction price in both cases was SEK 44.06 per share.

(In the original version of the announcement issued on January 6, 2025, the December 19, 2025, transaction was incorrectly referred to as an acquisition of shares.)

Attachments

• Publication-MTN-ATP-19-12-_2026-01-05
• Publication-MTN-ATP-17-12-_2026-01-05

Abivax Provides 2026 Corporate Outlook




Abivax Provides 2026 Corporate Outlook

Abivax Provides 2026 Corporate Outlook

• New market insights indicate significant future expansion of the ulcerative colitis (UC) market, with obefazimod well positioned to become a future market leader in the IBD space
• ABTECT Phase 3 Data Safety Monitoring Board (DSMB) meeting on December 18, 2025, found no new safety signals with over 80% of participants having completed the 44-week double blind maintenance trial
  
• ABTECT-UC Phase 3 maintenance topline results expected late Q2 2026, with a subsequent US regulatory filing planned for late 2026
• ENHANCE-CD Phase 2b induction trial of obefazimod in moderate-to-severely active Crohn’s disease (CD) ongoing; induction results expected late 2026
  
• 22 abstracts accepted for upcoming February 2026 European Crohn’s and Colitis Organization (ECCO) conference including oral presentation of obefazimod impact on fibrosis in in-vitro and preclinical models
  
• Cash runway expected into Q4 2027, after full debt reimbursement in Q4 2025
  

PARIS, France – January 7, 2026 – 10:05 PM CET – Abivax SA (Euronext Paris: FR0012333284 – ABVX / Nasdaq: ABVX) (“Abivax” or the “Company”), a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases, today announced its 2026 corporate outlook, highlighting new market insights, progress in the ABTECT-UC and ENHANCE-CD trials, and advances in its therapeutic pipeline. Updates from the ABTECT Phase 3 maintenance trial evaluating obefazimod for the treatment of moderate-to-severely active UC reinforce the therapy’s safety profile and inform potential future combination strategies.

Marc de Garidel, MBA, Chief Executive Officer of Abivax, commented: “As I reflect on our advances in 2025, I am beyond thankful for the patients and physicians who have helped advance our trials and for the Abivax employees and investors who supported this progress. This past year was a monumental one for Abivax as we announced positive data from our ABTECT Phase 3 8-week induction trial demonstrating obefazimod’s safety and potential as a first-in-class oral therapy for UC, we shared updates at major international meetings, and we closed a successful significant fundraising round. In 2026, I look forward to continuing this momentum as we evaluate the ABTECT-UC Phase 3 maintenance and ENHANCE-CD Phase 2 induction data and identify new opportunities for advancement of our pipeline. The findings shared today from the updated market research and DSMB safety analyses demonstrate the significant opportunity we have for making a real impact for the millions of patients inadequately addressed by current treatment options.”

LOOKING AHEAD TO 2026:

Ulcerative Colitis Market Opportunity

Multiple third-party industry analyses forecast significant growth in the ulcerative colitis (UC) market over the coming years, driven by increased use of advanced therapies and the launch of innovative mechanisms of action (MOAs). In one recently published report, worldwide UC sales are expected to more than double, increasing from $9.2 billion in 2025 to $21.2 billion by 2032.

In this context, market research following the announcement of the ABTECT Phase 3 induction results in July 2025 indicates that obefazimod may emerge as the future market leader in UC, potentially outperforming both currently approved therapies and anticipated future entrants, including TL1A inhibitors and oral IL-23 agents.

The research estimated that roughly 500K patients within the United States are currently on conventional therapies (5ASA’s/corticosteroids), with approximately 60% of these patients being moderate/severe (~300K patients). Physicians indicated they would likely initiate treatment with obefazimod for this population where reluctance to advanced therapies hinder their use.

ABTECT Phase 3 DSMB Update, Maintenance Topline Results, and Expected US Filing Timing

The ABTECT Phase 3 DSMB meeting occurred on December 18, 2025, and reported no new safety signals with over 80% of participants having completed the 44-week double blind maintenance phase of the trial.

Topline results from the ongoing ABTECT Phase 3 maintenance trial are expected in late Q2 2026 which has the potential to further demonstrate the durability of obefazimod treatment in UC and extended duration of therapy versus the currently available treatment options.

Ongoing New Drug Application (NDA) preparation includes planned engagement with the FDA in anticipation of planned filing in late 2026.

Pipeline Advancement

Obefazimod has a first-in-class mechanism of action that targets the site of inflammation and, together with preclinical evidence of a clear anti-fibrotic effect in Crohn’s disease, underscores its potential as a differentiated treatment option for patients with the condition. Detailed results, including 22 abstracts, will be shared at the 2026 European Crohn’s and Colitis Organization (ECCO) Annual Meeting taking place in Stockholm, Sweden on February 18-21, 2026.

The ENHANCE-CD Phase 2b, designed to evaluate the safety and efficacy of obefazimod in patients with moderate-to-severely active Crohn’s disease (CD), is actively progressing. The 12-week induction trial results are anticipated in late 2026 and will help inform the design of subsequent registrational studies.

Throughout 2026, initial preclinical results from ongoing studies evaluating obefazimod in combination with other agents (currently targeted combination MOAs include IL-23, a4b7, PDE-4 and AhR) will be shared, with a lead combination candidate selected to advance into development by year-end.

The company is also continuing to evaluate follow-on miR-124 enhancers in various chronic inflammatory models to further extend the mechanistic framework established with obefazimod. In parallel, the team is evaluating potential in-licensing opportunities for innovative, mechanistically complementary assets in inflammatory bowel disease to strengthen its portfolio.

Marc de Garidel continued: “This past year we have worked diligently to advance obefazimod in both ulcerative colitis and Crohn’s disease, showcasing the immense opportunity we have in expanding the current market and the potential for movement into first- and second-line therapy options. With our recently secured funding poised to support us into Q4 2027, we are now focused on completing our ABTECT Phase 3 maintenance trial to support potential NDA filing by the end of the year, completing our Phase 2b Crohn’s disease trial, and evaluating additional opportunities for advancement across our pipeline. We look forward to sharing additional updates throughout the year as we aim to offer a safer, more effective and durable treatment option for those impacted by chronic inflammatory diseases like UC and Crohn’s.”

Abivax 2026 Financial Reporting Calendar

March 23, 2026:                    Fiscal Year 2025 Financial Results

June 1, 2026:                        Q1 2026 Financial Results

June 5, 2026:                         Annual General Meeting / Extraordinary General Meeting

September 14, 2026:             H1 2026 Financial Results

December 14, 2026:              Q3 2026 Financial Results

About Abivax

Abivax is a clinical-stage biotechnology company focused on developing therapeutics that harness the body’s natural regulatory mechanisms to stabilize the immune response in patients with chronic inflammatory diseases. Based in France and the United States, Abivax’s lead drug candidate, obefazimod (ABX464), is in Phase 3 clinical trials for the treatment of moderately to severely active ulcerative colitis.

FORWARD-LOOKING STATEMENTS

This press release contains forward-looking statements, forecasts and estimates, including those relating to the Company’s business. Words such as “anticipate,” “expect,” “potential” and variations of such words and similar expressions are intended to identify forward-looking statements. These forward-looking statements include statements concerning the Company’s expectations for 2026, including the Company’s anticipated timing for topline results of its ABTECT Phase 3 maintenance and timing of the Company’s planned NDA filing, results of its ENHANCE-CD Phase 2 induction clinical trials, the potential therapeutic benefit and market opportunity of obefazimod, planned announcement of combination therapy, progress of the Company’s follow-on compound and expected cash runway. Although Abivax’s management believes that the expectations reflected in such forward-looking statements are reasonable, investors are cautioned that forward-looking information and statements are subject to various risks, contingencies and uncertainties, many of which are difficult to predict and generally beyond the control of Abivax, that could cause actual results and developments to differ materially from those expressed in, or implied or projected by, the forward-looking information and statements. A description of these risks, contingencies and uncertainties can be found in the documents filed by the Company with the French Autorité des Marchés Financiers pursuant to its legal obligations including its universal registration document (Document d’Enregistrement Universel) and in its Annual Report on Form 20-F filed with the U.S. Securities and Exchange Commission on March 24, 2025 under the caption “Risk Factors.” These risks, contingencies and uncertainties include, among other things, the uncertainties inherent in research and development, future clinical data and analysis, decisions by regulatory authorities, such as the FDA or the EMA, regarding whether and when to approve any drug candidate, as well as their decisions regarding labelling and other matters that could affect the availability or commercial potential of such product candidates, and the availability of funding sufficient for the Company’s foreseeable and unforeseeable operating expenses and capital expenditure requirements. Special consideration should be given to the potential hurdles of clinical and pharmaceutical development, including further assessment by the Company and regulatory agencies and IRBs/ethics committees following the assessment of preclinical, pharmacokinetic, carcinogenicity, toxicity, CMC and clinical data. Furthermore, these forward-looking statements, forecasts and estimates are made only as of the date of this press release. Readers are cautioned not to place undue reliance on these forward-looking statements. Abivax disclaims any obligation to update these forward-looking statements, forecasts or estimates to reflect any subsequent changes that the Company becomes aware of, except as required by law. Information about pharmaceutical products (including products currently in development) that is included in this press release is not intended to constitute an advertisement. This press release is for information purposes only, and the information contained herein does not constitute either an offer to sell or the solicitation of an offer to purchase or subscribe for securities of the Company in any jurisdiction. Similarly, it does not give and should not be treated as giving investment advice. It has no connection with the investment objectives, financial situation or specific needs of any recipient. It should not be regarded by recipients as a substitute for exercise of their own judgment. All opinions expressed herein are subject to change without notice. The distribution of this document may be restricted by law in certain jurisdictions. Persons into whose possession this document comes are required to inform themselves about and to observe any such restrictions.

Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference




Kiniksa Pharmaceuticals to Present at 44th Annual J.P. Morgan Healthcare Conference

LONDON, Jan. 07, 2026 (GLOBE NEWSWIRE) — Kiniksa Pharmaceuticals International, plc (Nasdaq: KNSA) today announced that it will present at the 44^th Annual J.P. Morgan Healthcare Conference on Monday, January 12, 2026 at 2:15 p.m. Pacific Time (5:15 p.m. Eastern Time).

A live webcast of Kiniksa’s presentation will be accessible through the Investors section of the company’s website at www.kiniksa.com. A replay of the event will also be available on Kiniksa’s website within approximately 48 hours after the event.

About Kiniksa
Kiniksa is a biopharmaceutical company dedicated to improving the lives of patients suffering from debilitating diseases by discovering, acquiring, developing, and commercializing novel therapies for diseases with unmet need, with a focus on cardiovascular indications. Kiniksa’s portfolio of assets is based on strong biologic rationale or validated mechanisms and offers the potential for differentiation. For more information, please visit www.kiniksa.com.

Every Second Counts! ^®

Kiniksa Investor & Media Contact
Jonathan Kirshenbaum
(781) 829-3949
jkirshenbaum@kiniksa.com

Genelux Corporation Announces Proposed Public Offering of Common Stock




Genelux Corporation Announces Proposed Public Offering of Common Stock

WESTLAKE VILLAGE, Calif., Jan. 07, 2026 (GLOBE NEWSWIRE) — Genelux Corporation (“Genelux”) (Nasdaq: GNLX), a late clinical-stage immuno-oncology company, today announced that it has commenced a proposed underwritten public offering of its common stock. In addition, Genelux expects to grant the underwriter a 30-day option to purchase up to an additional 15% of the number of shares of common stock sold in connection with the proposed offering. All shares are being offered by Genelux. The proposed offering is subject to market and other customary closing conditions, and there can be no assurance as to whether or when the proposed offering may be completed, or as to the actual size or terms of the proposed offering.

Lucid Capital Markets is acting as the sole book-running manager for the proposed offering.

The proposed offering is being made by Genelux pursuant to an effective shelf registration statement previously filed by Genelux with the U.S. Securities and Exchange Commission (the “SEC”) on February 2, 2024 and declared effective on February 13, 2024. This proposed offering is being made only by means of a preliminary prospectus supplement and the accompanying base prospectus that form a part of the registration statement. A preliminary prospectus supplement and the accompanying base prospectus relating to and describing the terms of the proposed offering will be filed with the SEC and may be obtained for free by visiting the SEC’s website at www.sec.gov. Copies of the preliminary prospectus supplement and the accompanying base prospectus relating to the proposed offering may also be obtained by contacting: Lucid Capital Markets, LLC, 570 Lexington Avenue, 40th Floor, New York, NY 10022.

This press release shall not constitute an offer to sell or the solicitation of an offer to buy these securities, nor shall there be any sale of these securities in any state or other jurisdiction in which such offer, solicitation or sale would be unlawful prior to the registration or qualification under the securities laws of any such state or other jurisdiction.

About Genelux

Genelux is a late clinical-stage biopharmaceutical company focused on developing next-generation oncolytic immunotherapies for patients suffering from aggressive and/or difficult-to-treat solid tumor types. Olvi-Vec currently is being evaluated in two U.S.-based clinical trials: OnPrime/GOG-3076, a multi-center, randomized, open-label Phase 3 registrational trial evaluating the efficacy and safety of Olvi-Vec in combination platinum-doublet + bevacizumab compared with physician’s choice of chemotherapy and bevacizumab in patients with platinum-resistant/refractory ovarian cancer; and VIRO-25, a multi-center, randomized, open-label Phase 2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet + physician’s choice of immune checkpoint inhibitor compared to docetaxel in non-small-cell lung cancer. Additionally, Olvi-Vec currently is being evaluated for dose selection in Olvi-Vec-SCLC-202, a China-based, multi-center, open label Phase 1b/2 trial evaluating the efficacy and safety of Olvi-Vec & platinum-doublet in recurrent small-cell lung cancer. The core of Genelux’s discovery and development efforts revolves around its proprietary CHOICE™ platform from which the Company has developed an extensive library of isolated and engineered oncolytic vaccinia virus immunotherapeutic product candidates, including Olvi-Vec. 

Forward-Looking Statements

This release contains or may imply “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, Section 21E of the Securities Exchange Act of 1934, as amended, and the Private Securities Litigation Reform Act of 1995. These forward-looking statements are not based on historical fact and include, but are not limited to, statements regarding the completion, timing and size of the proposed public offering and the anticipated grant to the underwriter of an option to purchase additional shares. Any forward-looking statements are based on management’s current expectations of future events and are subject to a number of risks and uncertainties that could cause actual results to differ materially and adversely from those set forth in or implied by such forward-looking statements. These risks and uncertainties include, but are not limited to, risks and uncertainties related to market conditions and satisfaction of customary closing conditions related to the proposed public offering. For a discussion of other risks and uncertainties, and other important factors, any of which could cause our actual results to differ from those contained in the forward-looking statements, see the section entitled “Risk Factors” in Genelux’s Quarterly Report on Form 10-Q for the fiscal quarter ended September 30, 2025 and in other filings that Genelux makes with the SEC from time to time. There can be no assurance that any of the forward-looking information provided herein will be proven accurate. These forward-looking statements speak only as of the date hereof and Genelux undertakes no obligation to update forward-looking statements, and readers are cautioned not to place undue reliance on such forward-looking statements.

Investor Contact

Austin Murtagh
Precision AQ
austin.murtagh@precisionaq.com

Media Contact

Ashley Murphy
Precision AQ
ashley.murphy@precisionaq.com

Source: Genelux Corporation